# OnCo record cetuximab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cetuximab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cetuximab" ;
  schema:name "Cetuximab"@en ;
  schema:description "Cetuximab is a chimeric antibody that blocks the EGFR growth receptor. It is used with FOLFIRI or FOLFOX in RAS wild-type, left-sided bowel cancer, with encorafenib in BRAF V600E disease, with KRAS G12C inhibitors, and with radiation or chemotherapy in head and neck cancer; RAS-mutant tumours gain nothing and may be harmed, so RAS testing comes first."@en ;
  schema:url <https://onco.cc/drugs/cetuximab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cetuximab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q420296> ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf>, <https://www.nice.org.uk/guidance/ta439>, <https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-EGFR)" ;
  schema:alternateName "Erbitux" ;
  onco:approval "US 2004: EGFR-expressing metastatic colorectal cancer (later restricted to RAS wild-type)", "US 2006: Head and neck squamous cell carcinoma with radiation", "US 2020: BRAF V600E mCRC with encorafenib", "US 2024: KRAS G12C mCRC with adagrasib", "EU 2004: EGFR-expressing metastatic colorectal cancer; later restricted to RAS wild-type", "England (NICE) 2017: Previously untreated EGFR-expressing RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI" ;
  onco:acceleratedApproval "US 2004-02-12: In combination with irinotecan for EGFR-expressing metastatic colorectal carcinoma refractory to irinotecan-based chemotherapy", "US 2004-02-12: As a single agent for EGFR-expressing metastatic colorectal carcinoma intolerant to irinotecan-based chemotherapy" ;
  onco:acceleratedApprovalConfirmed "US 2007-10-02: As a single agent for EGFR-expressing metastatic colorectal carcinoma intolerant to irinotecan-based chemotherapy", "US 2012-07-06: In combination with irinotecan for EGFR-expressing metastatic colorectal carcinoma refractory to irinotecan-based chemotherapy" ;
  onco:related <https://onco.cc/biomarkers/ras-wild-type/>, <https://onco.cc/biomarkers/kras-g12d/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/>, <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/merck/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/crystal-fire3/>, <https://onco.cc/trials/breakwater/>, <https://onco.cc/trials/nct07775287/>, <https://onco.cc/trials/nct07702032/>, <https://onco.cc/trials/nct04793958/>, <https://onco.cc/trials/nct06445062/>, <https://onco.cc/trials/nct07059221/>, <https://onco.cc/trials/nct07790510/>, <https://onco.cc/trials/nct06194656/>, <https://onco.cc/trials/nct07659795/>, <https://onco.cc/trials/nct06943820/>, <https://onco.cc/trials/nct03785249/>, <https://onco.cc/trials/nct05194995/>, <https://onco.cc/trials/nct07474727/>, <https://onco.cc/trials/nct07644559/>, <https://onco.cc/trials/nct07020221/>, <https://onco.cc/trials/nct07259590/>, <https://onco.cc/trials/nct05910827/>, <https://onco.cc/trials/nct05217446/>, <https://onco.cc/trials/nct05358249/>, <https://onco.cc/trials/nct07223047/>, <https://onco.cc/trials/nct04956640/>, <https://onco.cc/trials/nct07415031/>, <https://onco.cc/trials/nct07252739/>, <https://onco.cc/trials/nct04585035/>, <https://onco.cc/trials/nct07286149/>, <https://onco.cc/trials/nct02671435/>, <https://onco.cc/trials/nct06662786/>, <https://onco.cc/trials/nct05584670/>, <https://onco.cc/trials/nct06385678/>, <https://onco.cc/trials/nct06750094/>, <https://onco.cc/trials/nct07209111/>, <https://onco.cc/trials/nct06915142/>, <https://onco.cc/trials/nct05410145/>, <https://onco.cc/trials/mountaineer/>, <https://onco.cc/trials/nct05239741/>, <https://onco.cc/trials/nct00248287/>, <https://onco.cc/trials/nct05226871/>, <https://onco.cc/trials/nct06332092/>, <https://onco.cc/trials/prime/>, <https://onco.cc/trials/opus/>, <https://onco.cc/trials/calgb-80405/>, <https://onco.cc/trials/swog-s1406/>, <https://onco.cc/trials/new-epoc/>, <https://onco.cc/trials/n0147/>, <https://onco.cc/trials/petacc-8/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/>, <https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/>, <https://onco.cc/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/> .